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threatening ischemia (CLTI) was major amputation. In the
1980s bypass techniques developed and increased by number.
This led to the development of the vascular surgical specialty.
During the 1990s, the development of endovascular techniques
replaced aortoiliac open surgery for lower limb arterial disease
(LEAD), and over the last 10 years, an endovascular “tsunami” has
spread to all levels of the lower extremity arteries (Fig. S1; see
Supplementary Material). At the same time, patient de-
mographics have changed. Forty years ago, themost common risk
factor was smoking, while 20 years ago patients were predomi-
nantly both smokers and diabetics. Thereafter, smoking has
decreased, but a third group of patients has emerged. This group
comprises those who have been relatively healthy all their lives,
with no serious risk factors, and who are now approaching their
100th birthday: patients over 90 years of age. These patients live
at home and are mentally sound but, during their long life, have
developed universal atherosclerosis and, eventually, CLTI. This
group will grow markedly in the future.
In light of this, Fridh et al. write about an important topic in
their population-based observational cohort study on 11 000
patients from Swedvasc operated on in Sweden from 2008 to
2013.1 Outcome information was scrutinized using mandatory
national registers and case histories. Mean patient age was 77
years, and the age range demonstrates clearly the heteroge-
neity of patients: the youngest were 50 years of age (most
likely, younger patients were treated, but those aged < 50
years were excluded), whereas the oldest patient was 103
years of age. Male sex, renal insufﬁciency, diabetes, heart
failure, and atrial ﬁbrillation were independently associated
with both increased amputation risk and combined amputation
or death, whereas the use of low-dose acetylsalicylic acid (ASA)
and statins decreased signiﬁcantly the risk of these end points.
As numerous studies have been published on the risk factors
for complications after lower extremity revascularization, there
are few ﬁndings here that are worth underlining. First, the use
of low-dose ASA and statins was clearly protective. However,
the rate of statin use was disappointing, only 64%. Also, the
risk of negative end points was not higher in women, but was,
after adjusting for age, in men. Furthermore, the combination
of renal insufﬁciency, diabetes, and heart failure resulted in an
almost threefold increase in the risk of amputation and an
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study does not provide a concrete tool or even clear in-
structions for the patient selection. It is much easier to predict
patients with an excellent outcome than those who will not
beneﬁt from surgery. As the material is extensive, there could
have been enough patients to test or develop a scoring method
for everyday use to help vascular surgeons in decision-making.
At its best, revascularization helps to prevent amputation for
decades and enables independent living at home rather than in
an institution. It may also be harmful if patient selection is
inapt.2 In the future, we will encounter an increasing number
of very old individuals with CLTI and make decisions regarding
their revascularizations. How are we to distinguish the patients
who will not beneﬁt from revascularization but rather will have
a worse outcome due to the procedure? Patients who do not
recover from revascularization may not return home. Patients
on whom we use a lot of resources by attempting several re-
vascularizations may end up needing an amputation or die. I
hope we will have the courage to study this area and develop
guidelines for the future. As it is now, the guideline is that if a
patient is not living at home, is not mobile, and has dementia,
revascularization is not beneﬁcial. Moreover, among elderly
patients, an endovascular-ﬁrst or even endovascular-only
approach may be acceptable.3
In the end, we should be more aggressive with preventive
medication. Patients need more information on statins. The
beneﬁt has been proven at every turn, yet even in the Swedish
study the rate of statin use was not high.APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at
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